These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 29419480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
    Ishikawa A, Tokunaga M, Maeda J, Minamihisamatsu T, Shimojo M, Takuwa H, Ono M, Ni R, Hirano S, Kuwabara S, Ji B, Zhang MR, Aoki I, Suhara T, Higuchi M, Sahara N.
    J Alzheimers Dis; 2018; 61(3):1037-1052. PubMed ID: 29332041
    [Abstract] [Full Text] [Related]

  • 3. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
    Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, Dickson DW, Trojanowski JQ, Lee VM, Yoshida M, Hozumi I, Yoshiyama Y, van Swieten JC, Nordberg A, Suhara T, Zhang MR, Higuchi M.
    Brain; 2017 Mar 01; 140(3):764-780. PubMed ID: 28087578
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.
    Koga S, Ono M, Sahara N, Higuchi M, Dickson DW.
    Mov Disord; 2017 Jun 01; 32(6):884-892. PubMed ID: 28440890
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3.
    Kimura Y, Ichise M, Ito H, Shimada H, Ikoma Y, Seki C, Takano H, Kitamura S, Shinotoh H, Kawamura K, Zhang MR, Sahara N, Suhara T, Higuchi M.
    J Nucl Med; 2015 Sep 01; 56(9):1359-65. PubMed ID: 26182966
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Selective Disruption of Inhibitory Synapses Leading to Neuronal Hyperexcitability at an Early Stage of Tau Pathogenesis in a Mouse Model.
    Shimojo M, Takuwa H, Takado Y, Tokunaga M, Tsukamoto S, Minatohara K, Ono M, Seki C, Maeda J, Urushihata T, Minamihisamatsu T, Aoki I, Kawamura K, Zhang MR, Suhara T, Sahara N, Higuchi M.
    J Neurosci; 2020 Apr 22; 40(17):3491-3501. PubMed ID: 32265258
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PET-detectable tau pathology correlates with long-term neuropsychiatric outcomes in patients with traumatic brain injury.
    Takahata K, Kimura Y, Sahara N, Koga S, Shimada H, Ichise M, Saito F, Moriguchi S, Kitamura S, Kubota M, Umeda S, Niwa F, Mizushima J, Morimoto Y, Funayama M, Tabuchi H, Bieniek KF, Kawamura K, Zhang MR, Dickson DW, Mimura M, Kato M, Suhara T, Higuchi M.
    Brain; 2019 Oct 01; 142(10):3265-3279. PubMed ID: 31504227
    [Abstract] [Full Text] [Related]

  • 13. High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer's and Non-Alzheimer's Disease Tauopathies.
    Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, Takado Y, Shinotoh H, Sano Y, Yamamoto Y, Matsuoka K, Takuwa H, Shimojo M, Takahashi M, Kawamura K, Kikuchi T, Okada M, Akiyama H, Suzuki H, Onaya M, Takeda T, Arai K, Arai N, Araki N, Saito Y, Trojanowski JQ, Lee VMY, Mishra SK, Yamaguchi Y, Kimura Y, Ichise M, Tomita Y, Zhang MR, Suhara T, Shigeta M, Sahara N, Higuchi M, Shimada H.
    Neuron; 2021 Jan 06; 109(1):42-58.e8. PubMed ID: 33125873
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy.
    Wang X, Li W, Marcus J, Pearson M, Song L, Smith K, Terracina G, Lee J, Hong KK, Lu SX, Hyde L, Chen SC, Kinsley D, Melchor JP, Rubins DJ, Meng X, Hostetler E, Sur C, Zhang L, Schachter JB, Hess JF, Selnick HG, Vocadlo DJ, McEachern EJ, Uslaner JM, Duffy JL, Smith SM.
    J Pharmacol Exp Ther; 2020 Aug 06; 374(2):252-263. PubMed ID: 32493725
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [18 F]PM-PBB3 for clinical applications.
    Kawamura K, Hashimoto H, Furutsuka K, Ohkubo T, Fujishiro T, Togashi T, Arashi D, Sakai T, Muto M, Ogawa M, Kurihara Y, Nengaki N, Takei M, Nemoto K, Higuchi M, Zhang MR.
    J Labelled Comp Radiopharm; 2021 Mar 06; 64(3):109-119. PubMed ID: 33067819
    [Abstract] [Full Text] [Related]

  • 19. [11 C]PBB3 binding in Aβ(-) or Aβ(+) corticobasal syndrome.
    Cselényi Z, Wallin J, Tjerkoski J, Bloth B, Svensson S, Nennesmo I, Sunnemark D, Jelic V, Farde L, Svenningsson P.
    Synapse; 2023 Jul 06; 77(4):e22269. PubMed ID: 36951466
    [Abstract] [Full Text] [Related]

  • 20. In vivo positron emission tomography imaging of mitochondrial abnormalities in a mouse model of tauopathy.
    Barron AM, Ji B, Fujinaga M, Zhang MR, Suhara T, Sahara N, Aoki I, Tsukada H, Higuchi M.
    Neurobiol Aging; 2020 Oct 06; 94():140-148. PubMed ID: 32623260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.